<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The G20210A mutation in the prothrombin gene is associated with an increased risk of a first venous thromboembolic episode; few data are available about the long-term risk for recurrent venous <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> and it is not known whether or not carriers of the mutation should be recommended lifelong <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> treatment after the first <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>We investigated 624 patients, referred for previous objectively documented <z:hpo ids='HP_0002625'>deep venous thrombosis</z:hpo> of the legs or <z:hpo ids='HP_0002204'>pulmonary embolism</z:hpo>, to determine the risk of <z:hpo ids='HP_0004831'>recurrent thromboembolism</z:hpo> in heterozygous carriers of the G20210A mutation in the prothrombin gene after the first episode of venous <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>After exclusion of other inherited (anti-thrombin, protein C, <z:e sem="disease" ids="C0242666" disease_type="Disease or Syndrome" abbrv="">protein S deficiency</z:e> and factor V Leiden) or acquired (anti-<z:chebi fb="0" ids="16247">phospholipid</z:chebi> antibody syndrome) causes of <z:hpo ids='HP_0100724'>thrombophilia</z:hpo>, 52 heterozygous carriers of the prothrombin mutation were compared with 283 patients with <z:mpath ids='MPATH_458'>normal</z:mpath> genotype </plain></SENT>
<SENT sid="3" pm="."><plain>The relative risk for recurrent venous <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> was calculated between groups using a Cox's proportional hazard model </plain></SENT>
<SENT sid="4" pm="."><plain>The patients with the prothrombin mutation had a risk for spontaneous recurrent venous <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> similar to that of patients with <z:mpath ids='MPATH_458'>normal</z:mpath> genotype (hazard ratio 1.3; 95% CI, 0.7-2.3) </plain></SENT>
<SENT sid="5" pm="."><plain>The circumstances of the first event (spontaneous or secondary) did not produce any substantial variation in the risk for recurrence </plain></SENT>
<SENT sid="6" pm="."><plain>In conclusion, the carriers of the prothrombin mutation should be treated with oral <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> after a first <z:hpo ids='HP_0002625'>deep venous thrombosis</z:hpo> for a similar length of time as patients with a <z:mpath ids='MPATH_458'>normal</z:mpath> genotype </plain></SENT>
</text></document>